What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials
Posted inAlzheimer's Assn Alzheimer's Disease Amgen Inc Banner Alzheimer's Institute Biogen Inc Brain Clinical Trials Drugs (Pharmaceuticals) Eisai Co Ltd Elderly Eli Lilly and Company Food and Drug Administration Genetics and Heredity Government Accountability Office Hemorrhagic Stroke Institute for Clinical and Economic Review Kisunla Leqembi (Drug) Medicine and Health Novartis AG Retirement Communities and Assisted Living United States Villages, The (Fla)

What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials

Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information remained secret.
Officials Cast Doubt on a Dementia Drug, but Human Trials Continue
Posted inAcademic and Scientific Journals Alzheimer's Disease Cassava Sciences Inc City University of New York Clinical Trials Dementia Drugs (Pharmaceuticals) Falsification of Data Food and Drug Administration Regulation and Deregulation of Industry Securities and Commodities Violations Securities and Exchange Commission United States Wang, Hoau-Yan your-feed-science

Officials Cast Doubt on a Dementia Drug, but Human Trials Continue

The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement. Some experts wonder why clinical trials have not been stopped.
F.D.A. Approves a New Antipsychotic Drug
Posted inBristol Myers Squibb Company Clinical Trials Dopamine Drugs (Pharmaceuticals) Food and Drug Administration Karuna Therapeutics Inc Psychiatry and Psychiatrists Psychology and Psychologists Regulation and Deregulation of Industry Research Schizophrenia Therapy and Rehabilitation Weight

F.D.A. Approves a New Antipsychotic Drug

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.